{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-371265","form_type":"8-K","ticker":"LFVN","cik":"0000849146","company_name":"Lifevantage Corp","filed_at":"2026-08-27T20:06:14+00:00","discovered_at":"2026-08-27T20:07:09.636264+00:00","generated_at":"2026-08-27T20:07:42.475675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LifeVantage Q4 revenue down 23% to $42.4M; FY revenue down 20% to $182.6M","bullets":["Q4 revenue $42.4M (-23.1% YoY); Americas -24.8%, APAC/Europe -16.9%.","Q4 EPS $0.10 GAAP, $0.11 adjusted; FY EPS $0.40, adj $0.56.","FY revenue $182.6M (-20.1%); gross margin 77.6% on MindBody GLP-1 obsolescence.","Adj EBITDA Q4 $2.7M vs $4.8M; FY $13.7M vs $22.1M.","No FY27 guidance due to CEO transition; repurchased 336k shares ~$2M, $58.5M left."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-371265","json":"https://secwatch.observer/filing/0001193125-26-371265.json","markdown":"https://secwatch.observer/filing/0001193125-26-371265.md","text":"https://secwatch.observer/filing/0001193125-26-371265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849146/000119312526371265/0001193125-26-371265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849146/000119312526371265/lfvn-20260827.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-27T20:07:42.475675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}